Current Lipid-lowering Strategies for the Treatment of Diabetic Dyslipidemia: An Integrated Approach to Therapy

Marcus, Alan O.

doi:10.1097/00019616-200109000-00005

Cited by 4 publications

(2 citation statements)

References 142 publications

(133 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, in another study the improvement of carbohydrate metabolism was noted in patients with impaired glucose tolerance [153]. It is possible that hypertriglyceridaemia contributes to the induction of glucose intolerance and fibrates are effective in lowering triglycerides and enhancing insulin action [154]. Another possible explanation for the fenofibrate-induced improvement in insulin sensitivity could be the induction of fatty acid-binding protein as well as the stimulation of β-oxidation in skeletal muscles [155].…”

Section: A) Effects Of Fibrates On Carbohydrate Metabolismmentioning

confidence: 99%

Fenofibrate: Metabolic and Pleiotropic Effects

Tsimihodimos

Miltiadous

Daskalopoulou³

et al. 2005

CVP

View full text Add to dashboard Cite

Disturbances of lipoprotein metabolism represent one of the most important risk factors for vascular events. However, dyslipidaemic patients often have a number of additional abnormalities (such as endothelial dysfunction, hypertension, low-grade inflammation, haemostatic abnormalities and hyperuricaemia) that may accelerate the atherosclerotic process. Thus, the ideal lipid-modifying drug, along with exerting beneficial effects on lipoprotein metabolism, should also improve these coexisting disturbances. Fibric acid derivatives (fibrates) are a class of lipid-modifying drugs mainly used in patients with elevated triglyceride levels. These drugs mainly exert their actions via the activation of specific nuclear receptors called peroxisome proliferator-activated receptors alpha (PPARalpha). In this review, we summarize the current evidence suggesting that fenofibrate, one of the most widely used fibric acid derivatives, along with its well established actions on lipids also exerts several other antiatherogenic actions. Based on recently published studies, fenofibrate is a useful option for patients with primary combined dyslipidaemias or secondary dyslipidaemias, such as those associated with diabetes mellitus, metabolic syndrome or HIV infection. Additionally, in cases of refractory dyslipidaemia, the combination of fenofibrate with statins is a therapeutic option.

show abstract

Section: A) Effects Of Fibrates On Carbohydrate Metabolismmentioning

confidence: 99%

Fenofibrate: Metabolic and Pleiotropic Effects

Tsimihodimos

Miltiadous

Daskalopoulou³

et al. 2005

CVP

View full text Add to dashboard Cite

show abstract

“…It is possible that hypertriglyceridemia contributes to the induction of glucose intolerance and fibrates enhance insulin action by lowering TG (Steiner 1991; Avogaro et al 1995; Marcus 2001; Elisaf 2002). Another possible explanation for this improvement in insulin sensitivity could be the induction of FFA-binding protein as well as the stimulation of β-oxidation in skeletal muscles (Furuhashi et al 2002).…”

Section: Pleiotropic Actions Of Fenofibratementioning

confidence: 99%

Fenofibrate: a novel formulation (Triglide?) in the treatment of lipid disorders: a review

Τζιόμαλος¹,

Athyros²

2006

International Journal of Nanomedicine

View full text Add to dashboard Cite

Cardiovascular disease is the major cause of mortality worldwide and accounts for approximately 40% of all deaths. Dyslipidemia is one of the primary causes of atherosclerosis and effective interventions to correct dyslipidemia should form an integral component of any strategy aimed at preventing cardiovascular disease. Fibrates have played a major role in the treatment of hyperlipidemia for more than two decades. Fenofibrate is one of the most commonly used fibrates worldwide. Since fenofibrate was first introduced in clinical practice, a major drawback has been its low bioavailability when taken under fasting conditions. Insoluble Drug Delivery-Microparticle fenofibrate is a new formulation that has an equivalent extent of absorption under fed or fasting conditions. In this review, we will discuss the clinical pharmacology of fenofibrate, with particular emphasis on this novel formulation, as well as its lipid-modulating and pleiotropic actions. We will also analyze the major trial that evaluated fibrates for primary and secondary prevention of cardiovascular disease, the safety and efficacy profile of fibrate–statin combination treatment, and the current recommendations regarding the use of fibrates in clinical practice.

show abstract

The role of lipid management in diabetes

Ganda

2005

Cardiology Clinics

View full text Add to dashboard Cite

Current Lipid-lowering Strategies for the Treatment of Diabetic Dyslipidemia: An Integrated Approach to Therapy

Cited by 4 publications

References 142 publications

Fenofibrate: Metabolic and Pleiotropic Effects

Fenofibrate: Metabolic and Pleiotropic Effects

Fenofibrate: a novel formulation (Triglide?) in the treatment of lipid disorders: a review

The role of lipid management in diabetes

Contact Info

Product

Resources

About